Tumor heterogeneity across patients is a plausible explanation for this observation: although there are certainly frequently mutated driver genes in lung adenocarcinoma, such as EGFR, KRAS or STK11, only a minority of patients’ tumor is found positive for each of these mutations. Here, EGFR is linked to neoplasm.